NextCure reports Q2 net loss $15.4M; cash $86.4M; LNCB74 IND on track for year-end

NextCure, Inc.

2024-Q2 EPS reported -$1.16

Net loss $15.4M in Q2 2024 vs $17.9M in Q2 2023; R&D expenses $12.4M (down from $13.4M).
Cash & marketable securities $86.4M as of June 30, 2024; expected to fund operations into H2 2026.
LNCB74 (B7-H4 ADC) GLP tox studies completed; IND submission planned by year-end 2024.
NC410 + pembrolizumab ovarian cohort enrollment completed (16 additional patients); data expected Q4 2024.
NC181 (Alzheimer's) manufacturing initiated for tox studies; seeking partnering/funding for IND mid-2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.